Expanding Antigen-specific Tr1 Cells to Treat Autoimmunity

Simple item page
atmire.migration.oldid3737
dc.contributor.advisorSantamaria, Pedro
dc.contributor.authorAmbalavanan, Poornima
dc.date.accessioned2015-10-07T16:20:53Z
dc.date.embargolift2017-10-06T16:20:53Z
dc.date.issued2015-10-07
dc.date.submitted2015en
dc.description.abstractThe goal of a therapy against autoimmune diseases would be to blunt immune responses against self antigens, without impairing systemic immunity. Our lab has been developing a nanoparticle-based therapy which consists of disease-relevant peptide-MHC complexes coated on iron-oxide nanoparticles (NPs). We have demonstrated that the therapeutic effects exerted by these NPs are associated with expansion of antigen-specific T-regulatory-type-1 (Tr1) cells and immuno-suppression of autoantigen-loaded antigen presenting cells (APCs) in an IL-10 and TGF-beta-dependent manner. We have established that suppression is disease- and organ-specific and effective in different autoimmune diseases (EAE and CIA) and genetic background (C57BL/6 and C57BL/10). We have found that NPs coated with epitopes released downstream from a disease-triggering insult can be as effective in suppressing disease as those coated with disease-inducing epitopes. EAE-relevant pMHC II-NPs were not only effective in suppressing inflammation but also in promoting re-myelination. Thus this therapy provides a negative feedback loop that serves to counter autoimmune disease progression.en_US
dc.description.embargoterms2 yearsen_US
dc.identifier.citationAmbalavanan, P. (2015). Expanding Antigen-specific Tr1 Cells to Treat Autoimmunity (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca. doi:10.11575/PRISM/26040en_US
dc.identifier.doihttp://dx.doi.org/10.11575/PRISM/26040
dc.identifier.urihttp://hdl.handle.net/11023/2613
dc.language.isoeng
dc.publisher.facultyGraduate Studies
dc.publisher.institutionUniversity of Calgaryen
dc.publisher.placeCalgaryen
dc.rightsUniversity of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.
dc.subjectImmunology
dc.subject.classificationAutoimmune diseaseen_US
dc.subject.classificationEAEen_US
dc.subject.classificationTr1 cellsen_US
dc.titleExpanding Antigen-specific Tr1 Cells to Treat Autoimmunity
dc.typemaster thesis
thesis.degree.disciplineImmunology
thesis.degree.grantorUniversity of Calgary
thesis.degree.nameMaster of Science (MSc)
ucalgary.item.requestcopytrue
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.65 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Theses and Dissertations